Ozurdex 0.7 MG implants
Ended Awarded
- Contract number
- SPE2DX26F6WTE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $4,022
Award facts
- Contract value 100% obligated
- $4,021.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $4,021.56 to DMS Pharmaceutical Group Inc. for OZURDEX 0.7 mg implants on October 16, 2025. OZURDEX is a sustained-release dexamethasone implant used in ophthalmic applications for treating inflammation and macular edema. The award was issued under a firm fixed-price delivery order contract with no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The contract has an ultimate completion date of November 6, 2025.
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain. This delivery order was issued under the company's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes DLA to procure a comprehensive range of pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors providing specialized pharmaceutical products including oncology treatments, biologics, vaccines, and specialty surgical items to support recurring medical supply needs across the global military medical system.
Quick answers
Who was awarded contract SPE2DX26F6WTE?
SPE2DX26F6WTE was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on October 16, 2025.
How much is contract SPE2DX26F6WTE worth?
The government has obligated $4,022 on SPE2DX26F6WTE.
Is contract SPE2DX26F6WTE an order under another contract?
Yes. SPE2DX26F6WTE is a delivery order under SPE2DX15D9168, an indefinite delivery contract.
Was contract SPE2DX26F6WTE competed?
The extent of competition for SPE2DX26F6WTE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award